Immunotherapy in lung cancer: New concepts

被引：2
作者：
Goubet, A. -G. [1 ]
Livartowski, A. [2 ]
Romano, E. [1 ,2 ]
机构：
[1] INSERM, U932, Ctr Immunotherapie Canc, 26 Rue Ulm, F-75005 Paris, France
[2] Inst Curie, Dept Oncol Med, F-75005 Paris, France
来源：
REVUE DES MALADIES RESPIRATOIRES | 2018年 / 35卷 / 06期
关键词：
Lung cancer; Immunotherapy; Immune Checkpoint; TIM3; LAG3; REGULATORY T-CELLS; ANTITUMOR IMMUNITY; INHIBITORY RECEPTORS; PD-1; LAG-3; TIM-3; PEMBROLIZUMAB; CARBOPLATIN; EXHAUSTION; GALECTIN-9;
D O I：
10.1016/j.rmr.2018.03.001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Improvements in knowledge about the complexity of the tumor microenvironment have paved the way for a revolution in lung cancer treatment with the emergence of immune checkpoint inhibitors. The immune checkpoints negatively regulate immune cells and lead to a dormant state: the immune cells are then unable to interact effectively with their targets. The immune checkpoint inhibitors are monoclonal antibodies that block immune checkpoints and permit reactivation of the immune response against the tumor. Although immune checkpoint inhibitors are effective as monotherapy, several other immune targets exist. The better understanding of the involvement of these new targets in the immune response against tumors is leading to the design of new compounds and new therapeutic approaches. (C) 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：642 / 651
页数：10
相关论文
共 42 条
  • [1] Expression and regulation of immune-modulatory enzyme Indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation
    Aldajani, Wejdan A.
    Salazar, Fabian
    Sewell, Herb F.
    Knox, Alan
    Ghaemmaghami, Amir M.
    [J]. ONCOTARGET, 2016, 7 (36) : 57606 - 57617
  • [2] Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer
    Astigiano, S
    Morandi, B
    Costa, R
    Mastracci, L
    D'Agostino, A
    Ratto, GB
    Melioli, G
    Frumento, G
    [J]. NEOPLASIA, 2005, 7 (04): : 390 - 396
  • [3] ENTPD1/CD39 is a promising therapeutic target in oncology
    Bastid, J.
    Cottalorda-Regairaz, A.
    Alberici, G.
    Bonnefoy, N.
    Eliaou, J-F
    Bensussan, A.
    [J]. ONCOGENE, 2013, 32 (14) : 1743 - 1751
  • [4] Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
    Bastid, Jeremy
    Regairaz, Anne
    Bonnefoy, Nathalie
    Dejou, Cecile
    Giustiniani, Jerome
    Laheurte, Caroline
    Cochaud, Stephanie
    Laprevotte, Emilie
    Funck-Brentano, Elisa
    Hemon, Patrice
    Gros, Laurent
    Bec, Nicole
    Larroque, Christian
    Alberici, Gilles
    Bensussan, Armand
    Eliaou, Jean-Francois
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (03) : 254 - 265
  • [5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [6] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [7] Vascular CD39/ENTPD1 Directly Promotes Tumor Cell Growth by Scavenging Extracellular Adenosine Triphosphate
    Feng, Lili
    Sun, Xiaofeng
    Csizmadia, Eva
    Han, Lihui
    Bian, Shu
    Murakami, Takashi
    Wang, Xin
    Robson, Simon C.
    Wu, Yan
    [J]. NEOPLASIA, 2011, 13 (03): : 206 - U34
  • [8] CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
    Fourcade, Julien
    Sun, Zhaojun
    Pagliano, Ornella
    Guillaume, Philippe
    Luescher, Immanuel F.
    Sander, Cindy
    Kirkwood, John M.
    Olive, Daniel
    Kuchroo, Vijay
    Zarour, Hassane M.
    [J]. CANCER RESEARCH, 2012, 72 (04) : 887 - 896
  • [9] Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
    Grosso, Joseph F.
    Goldberg, Monica V.
    Getnet, Derese
    Bruno, Tullia C.
    Yen, Hung-Rong
    Pyle, Kristin J.
    Hipkiss, Edward
    Vignali, Dario A. A.
    Pardoll, Drew M.
    Drake, Charles G.
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 182 (11) : 6659 - 6669
  • [10] An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection
    Han, P
    Goularte, OD
    Rufner, K
    Wilkinson, B
    Kaye, J
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (10) : 5931 - 5939
12345